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Antigen-specific stem-like memory CD8+ T cells (Tscm) have a series of stem cell
characteristics, including long-term survival, self-renewal, anti-apoptosis and persistent
differentiation into cytotoxic T cells. The effective induction of tumor-specific CD8+ Tscm
could persistently eradicate tumor in pro-tumor hostile microenvironment. This study
was to investigate the role of CD40 in HPV16-specific CD8+ Tscm induction and its
anti-tumor function. We found that CD40 activation accelerated vaccine-induced HPV16
E7-specific CD8+ Tscm formation. Comparing to other HPV-specific CD8+ T cells, CD8+
Tscm were found to be stronger and long-term anti-tumor function, in vivo and in vitro,
even in the adoptive cellular transferring model. Furthermore, high frequencies of Tscm
might prevent the HPV infection to move on to the development of cancer. And the CD40
effect on Tscm involvedWnt/β-catenin activation. Our study suggest that CD40 activation
supports the generation of tumor-specific CD8+ Tscm, thus providing new insight into
cancer immunotherapy.
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INTRODUCTION
Approximately 57,000 new cases of cervical cancer all over the world take place in 2018, making
it the 2nd most common female cancer and the 4th fatal female malignancy worldwide (1). HPV
vaccines are proved to be preventive from human papillomavirus infection and related cervical
cancer, but ineffective to the established cervical cancer (2). The HPV-specific cytotoxic T cells
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dominate anti-tumor immunity against cervical cancer. Recently,
multiple CD8+ T-based adoptive cells therapies (ACT), including
TIL, CAR-T and TCR-T, have some promising therapeutic
functions on cancer immunotherapy. However, the hostile tumor
microenvironment and short-term persistence in vivo obviously
limit the effectiveness of the ACT therapy.
Memory T cells are characterized as the long-term persistence,
resistance to apoptosis and high sensitiveness to little antigen
challenge. The memory T cells previously include central
memory T cells (Tcm) and effector memory T cells (Tem).
Recently, a novel subset of T memory cells with strong stemness
(Tscm) was found, comparing to the Tcm and Tem, Tscm are
characterized with decades-years persistence in vivo, intensive
self-renewing ability, consistent differentiation to Tcm, and high-
resistance to apoptosis (3). Tscm cells play a significant long-term
protective role from infections and cancers (4–7). The induction
of Tscm may be a potential strategy for long-term effective
ACT therapy.
As a member of the tumor necrosis factor receptor family,
CD40 expresses in a range of immune cells, including DCs, B
cells and activated CD8+ T cells (8). In recent years, CD40
activation can strengthen the immune responses induced by
various vaccines (8, 9) and can generate long-time anti-tumor
effects (10). CD40 agonist combination with chemotherapy have
a higher response in various solid tumors than chemotherapy
alone (11). And a tumor-targeting CD40 bispecific compound,
ABBV-428, has been applied for clinical immunotherapy (12). It’s
reported that the activation of CD40/CD40L pathway in APCs
induces the transformation of naïve CD8+ T cells into CD8+
central memory T cells (13, 14). However, the effect of CD40 in
mediating the formation of Tscm, especially tumor-specific Tscm,
is still unclear.
Activating CD40 signaling maximally stimulates T cell
production of Wnt10b, resulting in Wnt signaling activation
(15, 16). And increasing evidences reveal that Wnt/β-catenin
signaling can promote CD8+ T cell memory formation and
enhance their functionality (17, 18). Tscm cells are the least
differentiated subset and possess characteristics of conventional
memory T cells (3). Therefore, it’s very likely that Wnt/β-
catenin signaling is a critical player in the process of generating
Tscm. Luca et.al. demonstrated the key role for Wnt/β-catenin
signaling in the maintenance of stemness in memory CD8+
T cells (18).
Therefore, our laboratory discovered a possible mechanism
of CD40 triggering a long-term antitumor immunity based on
HPV16 specific Tscm, and developed an optimal immunization
pattern for therapeutic purpose, which may provide a promising
therapeutic strategy for HPV16-positive tumors.
MATERIALS AND METHODS
Cell Lines
Mouse cervical cell line TC-1 with HPV16 E7+ was purchased
from the American Type Culture Collection (ATCC). TC-1
cells were cultured in DMEM (Gibco) supplemented with 10%
FBS (Gibco).
Mice
Six- to eight-week-old female C57BL/6 mice and nude mice
were obtained from the Experimental Animal Center at Southern
Medical University (Guangzhou, PR China). Animal care and
experiments were approved by the Institutional Animal Research
Ethics Committee of Southern Medical University.
Clinical Samples
Peripheral blood mononuclear cells (PBMCs) were isolated
from voluntarily consenting only HPV16 positive or CSCC
patients without preoperative radiotherapy or chemotherapy
at the department of Gynecological Oncology of the first
affiliated hospital of Guangzhou medical university (Guangzhou,
China) or healthy donors between 2018 and 2019 using
FicollPaque Plus (GE Healthcare). Detailed information on
clinical specimens are summarized in Table S1. The study was
approved by the Institutional Research Ethics Committee of
Southern Medical University.
Peptides, Antibodies, and Reagents
Optimal peptides based on HPV16 E7(RAHYNIVTF) peptides
were synthesized by Chinese Peptide Ltd. The PE-labeled H-
2Db/E7tetramers and HLA-A∗0201 HPV16 E7 tetramers were
purchased from MBL. The antibodies used in our study included
anti-mouse CD8a (Clone:KT15, MBL), CD44(Clone:IM7,
thermo fisher scientific), CD62L (Clone:MEL-14, thermo fisher
scientific), IFN-γ (Clone: XMG1.2, thermo fisher scientific),
EOMEs (Clone:Dan11mag, thermo fisher scientific), T-bet
(Clone: eBio4B10, thermo fisher scientific) and β-catenin
(Clone: 4627S, CST) and anti-human CD8a (Clone:T8,
MBL, S1004, BSbio), CD62L (Clone:DREG-56, Biolegend),
CD95(Clone:DX2, Biolegend), CD45RA (Clone: HI100,
Biolegend) and CD122(Clone: TU27, Biolegend). The 7-AAD
and Fixable Viability Dyes were purchased from thermo fisher
scientific. LEAFTM purified anti-mouse CD40 (Clone:1C10)
was purchased from Biolegend. The vaccine adjuvant Poly (I:C)
(HMW) VacciGradeTM was purchased from invivogen.
Immunization and Establishment of
Therapeutic Models
1 × 106 TC-1 cells were injected subcutaneously into the
right flank of C57BL/6 mice. After 7 days, tumor-bearing mice
were immunized with following immunization strategy groups,
selectively: PBS group, HPV16 E7 peptide group, HPV16 E7 plus
50 µg Poly (I:C) group, and HPV16 E7 plus 50 µg Poly (I:C) and
20 µg aCD40 mAb group. The mice were immunized for 3 times
every 7 days via i.v. Tumor volume was measured every 3 days
and calculated by the formula: volume = (width)2 x length/2.
Mice were euthanized when tumor size reached 1.5 cm3.
Flow Cytometry Analysis
For tetramer staining, peripheral blood cells and splenocytes were
incubated with indicated antibodies plus PE-labeled H-2Db/E7
tetramer for 30min at 4◦C and 7-AAD was added to differentiate
dead cells.
For Intracellular staining of IFN-γ, splenocytes were collected
and incubated with TC-1 cells (1:1) in the presence of BFA for
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6 h to block the secretion of IFN-γ. Then cells were collected
and incubated with anti-CD8a for 30min at 4◦C. Following
membrane staining, cells were fixed and permeabilized with
Fixation/Permeabilization buffer (Thermo fisher scientific). Cells
were then intracellularly stained with anti-IFNγ for 30min at
4◦C. The fluorescence was evaluated on the Fortessa (BD) and
the data was analyzed by using FlowJo software.
For intranuclear staining of EOMEs, T-bet and β-catenin,
splenocytes were collected and incubated with anti-CD8a for
30min at 4◦C. Following membrane staining, cells were fixed
and permeabilized with Transcription Factor Staining buffer
(Thermo fisher scientific). Cells were then intranuclear stained
with anti- EOMEs, T-bet and β-catenin for 30min at 4◦C. The
fluorescence was evaluated on the Fortessa (BD) and the data was
analyzed by using FlowJo software.
Adoptive Cell Transfer
The murine splenocytes were stained with anti-CD8a,
CD44, CD62L plus H-2Db/HPV16E7 tetramer and were
sorted on MoFlo XDP (Beckman coulter). The sorted
cells of Tscm (CD8+Tet+CD44−CD62L+), Tcm (CD8+Tet+
CD44+CD62L+), Tem (CD8+Tet+CD44+CD62L−) were
selectively injected into nude mice radiated 2.4Gy. 5 weeks later,
1x106 TC-1 cells were transplanted into mice via s.c. in the right
flank. Tumor growth was monitored as described previously.
Cell Counting Kit-8 (CCK-8) Assay for Cell
Viability
A CCK8 assay (Beyotime) was used to determine the effect of
murine splenocytes from different groups on TC-1 cells. Briefly,
TC-1 cells were seeded in 96-well plates at a concentration of
9000 cells per well and incubated with murine splenocytes at
indicated E/T ratios for 48 h. At the indicated time point, 10
µL of CCK-8 assay reagent was added and the plates were
incubated for another 2 h. Absorbance was detected at 450 nm.
The experiments were performed with three replicate wells
per sample.
Database
Level 2 gene expression profile (level 2 data) for CESC
patients was obtained from the UCSC Xena website (https://
xenabrowser.net/datapages/). The gene expression profile was
measured experimentally using the Illumina HiSeq 2000 RNA
Sequencing and showed the gene-level transcription estimates,
as in log2(x+1) transformed RSEM normalized count. Clinical
data such as survival and outcome were also downloaded
from UCSC Xena website. Relationship between CD40 and
CD62LCD45RACD95CD122 was calculated by using an R
package ggstatsplot.
Statistical Analysis
Statistical analysis was conducted using T-test, and analysis
between multiple groups was performed by one-way analysis
of variance (ANOVA). Correlation analysis was performed
using the log-rank test. Differences were considered statistically
significant at P < 0.05.
RESULTS
CD40 Enhances the Long-Term
HPV-Specific Anti-Tumor Immunity in vivo
To study anti-tumor effects of different immunizations using a
peptide epitope fromHPV16 E7, we immunizedHPV16+ tumor-
bearingmice withHPV16 E7 peptide in combination with polyIC
and aCD40. Comparing with controls, CD40 activation groups
could obviously suppress TC-1 tumor growth (Figure 1A).
To confirm the specific anti-tumor immunity, the splenocytes
were harvested and adoptively transferred into nude mice, and
prevented the TC-1 tumor challenge effectively (Figure 1B).
CD40 Induces the HPV16-Specific CD8+ T
Cell Against Cancer Cells
To explore anti-tumor effect of specific CD8+ T cells, we detected
the percentage of HPV16 E7 specific (tetramer positive) CD8+
T cells in mouse blood, spleen and lymph node. As shown in
Figure 2A, CD40 stimulation induced more HPV16 E7 specific
CD8 formation than other groups. Consistently, CD8+ T cells
fromCD40-activatedmice producedmore IFN-γ after co-culture
with TC-1 cells (Figure 2B), and eliminated more HPV16+ TC-1
cells in a dose-dependent manner (Figures 2C,D).
CD40 Facilitates HPV16-Specific CD8+
Tscm Formation
Long-term immune memory toward tumor antigen plays
a critical role in anti-tumor effects (10). To investigate
potential mechanisms underpinning CD40-amplified
antitumor immunity, we analyzed the memory subsets of
specific CD8T cells by staining with CD44 and CD62L. The
experiment demonstrated in Figure 3A shows CD40 stimulation
induced more systemic HPV-specific CD8+ Tscm than other
immunizations in spleen and lymph node, but not non-specific
Tscm (Figures 3A,B). The transcriptional factors Eomes and
T-bet balanced the differentiation and maintenance of CD8
memory T cells (19, 20). Therefore, we found that CD40
stimulation enhanced Eomes expression, but down-regulated
T-bet expression (Figures 3C–F).
Adoptive Transfer of HPV16 E7 Specific
Tscm Represses Cancer Growth
To further verify the critical role of Tscm in preventing tumor,
we sorted the subsets of HPV16 E7 specific CD8+ memory
T cells (Tem, Tcm, Tscm) from CD40 immunized mice, and,
respectively transferred different memory T cells into nude mice
(Figure 4A). The data in Figure 4B shows the HPV16 specific
CD8 T+ cells differentiation in Tscm group was significantly
stronger than the groups of Tcm and Tem (Figures 4B,C), and
Tscm differentiated into specific Tcm and Tem after TC-1 cells
challenge (Figure 4D). Consistently, the adoptive transferring of
CD8+ Tscm significantly repressed the tumor growth, comparing
to the control groups (Figures 4E,F).
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FIGURE 1 | Anti-tumor effects induced by different immunization. (A) Mice (n = 3 per group) were inoculated (s.c.) with 1 ×106 TC-1 cells and vaccinated (i.v.) 6 days
later with PBS, HPV16 E7 peptide alone, peptide plus polyIC, peptide and polyIC plus αCD40 mAb. (B) In the preventive model, nude mice after 2.4Gy radiation were
injected with 10 million of total splenocytes of the immunized mice when TC-1 tumor appeared. Tumor growth was measured (two opposing diameters) and recorded
once every 3 days. Data shown represent three independent experiments with similar results. *p < 0.05, **p < 0.01, ***p < 0.001, n.s, p > 0.05.
Wnt/β-catenin Signaling Involves With
CD40-Inducible HPV16-Specific CD8 Tscm
Cells
Wnt/β-catenin signaling can promote CD8+ T cell memory
formation and enhance their functionality (17, 18). To further
study the possible intrinsic mechanism of CD40 function on
specific CD8 Tscm cells, the critical regulator of β-catenin in
CD8T cells was examined. CD40 stimulation was proved to
upregulate β-catenin level in CD8+ T cells (Figures 5A,B). For
making certain the role of Wnt/β-catenin signaling, β-catenin
inhibitor (XAV-939) was found to block the CD40-mediated
HPV16-specific CD8+ Tscm differentiation. The percentage of β-
catenin in CD8 cells treated with aCD40mAb plus XAV-939 was
much lower than aCD40mAb alone (Figures 5C–E). Consistent
with results in vivo, it was observed that after aCD40mAb
stimulation for 48 h, the proportion of HPV16 E7-specific CD8
Tscm cells came up to 4.34%, but blockade of Wnt/β-catenin
by incubating with XAV-939 reversed the effect (Figures 5F,G).
These data suggest that Wnt/β-catenin activation is necessary for
CD40 supportive function on HPV16-specific CD8 Tscm cells.
High Frequencies of Tscm Might Prevent
the HPV Infection to Move on to the
Development of Cancer
Lastly, to confirm the association between our hypothesis
and clinical prognosis, HPV16-specific Tscm cells marked
by tetramer staining were examined in PBMC of healthy
female donors (n = 6), HPV16 infected patients (n = 6) and
HPV16 positive cervical cancer patients (n = 6). As shown
in Figures 6A,B, the level of HPV16-specific CD8T cells was
higher in patients with HPV16 without tumor, comparing to the
cancer patients. Moreover, the level of human HPV16-specific
CD8+ Tscm (CD8+tet+CD45RA+CD62L+CD95+CD122+)
in HPV16 infected patients without tumor, was higher than
that of cancer patients (Figures 6C,D), indicating that HPV16-
specific Tscm cells might prevent the HPV infection to
move on to the development of cervical cancer. Correlation
analysis demonstrated CD40 protein was positively associated
with stem cell marker CD62L+CD45RA+CD95+CD122+
(Figure 6E). Kaplan-Meier survival estimates, based
on dichotomized protein expression data, subsequently
confirmed that patients with cervical cancer with high
CD40 and high CD62LCD45RACD95CD122 protein
expression had significantly longer OS (CD40, p < 0.05;
CD62LCD45RACD95CD122, p < 0.05) (Figures 6F,G).
DISCUSSION
Adoptive T-cell immunotherapy is a promising approach to
cancer therapy, especially TCR or CAR gene engineered effector
T cells. However, there are functional challenges of engineered
T cells therapy, including short-persistence of T cells in the
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FIGURE 2 | Evaluation of specific CD8+ T cells elicited by immunized mice and ability of killing TC-1 cells in vitro. (A) Frequencies of HPV16-specific CD8+ T cells in
blood, spleen and lymph node from each group (3 mice/group) were measured by tetramer analysis 1 months after prime and boost induced by immunization using
various vaccine formulations. (B) Splenocytes of the primed and boosted mice (n = 3 per group) were co-cultured with TC-1 cells for 6 h and analyzed for IFNγ in
CD8+ T cells. (C) The cytotoxicity of the immunized mouse splenocytes was studied by co-culturing them with TC-1 cells. Pictures were taken after overnight
co-culture. Scale bar = 100µm. (D) CCK8 assay was then performed to determine the remaining live TC-1 cells after splenocytes were rinsed away. The CCK8 data
of TC-1 tumor cells co-cultured with different ratios of splenocytes was compared to CCK8 data of TC-1 tumor cells alone to calculate % of live cells. Shown is the
dose-dependent killing of TC-1 cells by splenocytes. Error bars represent the mean ± SD of three independent experiments. ***p < 0.001, n.s, p > 0.05.
tumor microenvironment (21, 22). Therefore, the long-lived
T cell is an urgent need for cancer immunotherapy. Our
findings demonstrated that effective induction of antigen-specific
CD8+ Tscm with CD40 activation evoked long-term anti-tumor
immunity. Firstly, CD40 stimulation induced long-lived HPV-
specific CD8+ Tscm, which consistently differentiated into Tcm
and Tem, and evoked persistent anti-tumor response. Secondly,
CD40 stimulation activated Wnt/β-catenin to reprogramme
stem-like characteristic of CD8+ T cells. Lastly, the clinical
evidence confirmed that CD40 induced HPV16-specific Tscm
cells need to be enhanced in cancer patients to prevent further
progression of the disease or to induce even cure, and may be
adopted as a potent immunotherapy.
As novel memory T cells, Tscm cells obviously have enhanced
characteristics of the conventional memory T cells. Comparing
to the Tcm and Tem, Tscm could be recalled with little antigen
stimulation threshold (3). Tscm could be effective surveillance
on little cancer cells appearance, and eliminate them at the early
phase. Our data suggested that Tscm were very different from
other memory T cell subsets in anti-tumor effects, including
Tem and Tcm. Compared with Tem and Tcm, Tscm have a
lower ratio but a greater life span and superior anti-tumor
response (23). Furthermore, the multiple hostile components
of cancer cells and stromal cells in tumor microenvironment,
such as immune checkpoints, hypoxia, amino acid deprivation,
block anti-tumor T cells function and survival. The superior
ability of self-renewing and apoptosis-resistance contributes to
Tscm survival in tumor. Expression of CD95 by long-lived
memory T cells promotes cell proliferation by inducing TCR-
β-catenin signaling, which is important for their self-renewal
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FIGURE 3 | HPV16 E7 peptide in combination with polyIC and aCD40 generates more Tscm and affects the expression of EOMEs and T-bet. (A,B) Distributions of
HPV16 E7 specific and non-specific CD8+ memory T cells in spleen and lymph node were measured by FCS analysis 1 months after prime and boost induced by
immunization using various vaccine formulations. Frequencies of EOMEs (C,D) and T-bet (E,F) gated on CD8+ T cells in spleen and lymph node were measured by
FCS analysis 1 months after prime and boost induced by immunization using various vaccine formulations. Error bars represent the mean ± SD of three independent
experiments. **p < 0.01, ***p < 0.001, n.s, p > 0.05.
and persistence (24). The levels of anti-apoptotic genes such
as BCL2 and MCL1 are specifically upregulated in Tscm cells,
which accounts for their enhanced survival capacity when little
or no antigen exists (25). More importantly, multidimensional
scaling analysis demonstrated that Tscm cells were the most
similar to naïve T cells because there were only 75 different
genes between them compared to 157 and 226 for Tcm and
Tem cells (3), thus which could continuously differentiate into
Tcm, Tem and CTL under antigen stimulation. Because of the
potent ability of Tscm, the Tscm induction becomes an important
indicator for estimating various vaccines because of its special
characteristics, such as the yellow fever vaccine YF-17D (26) and
the AIDS experimental vaccine RV144(27). This may bring a new
hope to solve existing problems in current rising T cell adoptive
immunotherapy, where TCR or CAR gene engineered effector
T cells easily become exhaustion and are hard to survive for a
Frontiers in Immunology | www.frontiersin.org 6 May 2020 | Volume 11 | Article 1012
Zhang et al. CD40 Accelerates Tscm Formation
FIGURE 4 | Adoptive transfer of HPV16 E7 specific Tscm represses cancer growth. (A–C) Frequencies of CD8+ T cell in blood were measured by FCS analysis 1st
and 5th week after injecting different subtypes of HPV-16 specific memory T cells (Tem, Tcm, Tscm) induced by immunized C57BL/6 mice into nude mice. (D) After
injecting different memory T cells (Tem, Tcm, Tscm) induced by immunized C57BL/6 mice into nude mice, distributions of HPV16 specific CD8+ memory T cells in
blood were measured by FCS analysis 1st and 5th week. (E,F) Nude mice (n = 3 per group) after 2.4Gy radiation were injected with different memory T cells of the
immunized mice and were inoculated (s.c.) with 1 × 106 TC-1 cells. Tumor growth was measured (two opposing diameters) and recorded once every 3 days. Data are
representative of three independent experiments with similar results. ***p < 0.001.
long time (28). Clinical trials have demonstrated that only 1700
Tscm clones persisted and maintained their properties for up to
12 years in patients with genetically modified T memory stem
cells (29). The engineered Tscm cells have been proved to be
safe, functional and decade-long survival, which is particularly
attractive to be used for adoptive immunotherapies (23).
In our previous study, we proved that Tscm induced by
the immunization with lv-expressing epitope-optimized antigen
peptides priming and peptide boosting could undergo more in
vivo expansion than Tcm and Teff upon re-encountering antigen
and had a long-lasting anti-tumor effect (7). Recently, many
groups have reported that Wnt or Notch signaling induced-
Tscm cells could provide breakthrough in developing target-
specific T cell therapy (3). Here, we proposed a novel strategy
of generating peptide vaccine-induced Tscm cells and certified
that the adoptive transfer of low number of T cells from Tscm
subset can long term maintain immune responses and effectively
prevent tumor recurrence in vivo. A number of clinical trials
about peptide vaccines treating tumors have been developed for
many years. Most of studies concentrate on melanomas because
of its systemic tolerance toward conventional therapies and high
immunogenicity. Obviously, peptide vaccines possess extremely
high security, easy synthesis and purification and induce specific
immune response comparing with other immunotherapies while
they may be easy to degrade within a short time and acquire
short-lived effects. Here, we attempt to improve current therapy
toward cervical cancer, especially its recurrence, according to
using CD40-based HPV16 E7 vaccine which solves problems
existing in peptide vaccines. Moreover, our strategy promotes
long-term protection of vaccine comparing with HPV vaccine
currently on the market. The combinatorial use of peptide
vaccines with CD40 antibody and TLR3 agonists acquires not
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FIGURE 5 | CD40 regulates Wnt/β-catenin signaling to elicit a high level of HPV16-specific CD8 Tscm cells. (A,B) Flow analysis of β-catenin in CD8+ T cells from
C57BL/6 mice immunized by different vaccination strategies. (C) Splenocytes from immunized mice were treated with aCD40mAb plus DMSO or aCD40mAb plus
XAV-939 for 48 h, then the percentage of β-catenin in CD8+ T cells was measured (D,E) and HPV16 E7 specific CD8+ Tscm cells (F,G) was detected by FCS
analysis. Error bars represent the mean ± SD of three independent experiments. ***p < 0.001.
only greater therapeutic efficacy but also positive preventive
effect. Our method has an advantage in generating Tscm cells
compared with Wnt (18) or Notch signaling activators (30) since
they need to convert memory T cells into Tscm cells but we
can directly gain antigen-specific Tscm cells. In our study, it’s
worth noting that CD40 vaccine can only inhibit larger tumor
(>1 cm3) for several days but can completely eliminate smaller
tumor (<0.2 cm3), what’s more, CD40 vaccine can suppress the
growth of tumor in early stage until it disappears. The meta-
analysis identified 14 randomized clinical trials that the early or
late use of targeted drugs has no effect on the survival curve
of patients with non-small cell lung cancer, but the overall risk
of death in patients who take the first use of immune drugs is
more than 30% lower than that of patients who take immune
drugs after getting other therapies is also in agreement with our
data (31). These data indicates CD40-based peptide vaccines are
suitable to patients with less tumor burden or greater risk of
recurrence. Of course, severe systemic toxicity of CD40 antibody,
including elevated liver enzymes and cytokine release syndrome,
should be noticeable in clinical studies. However, Fransen et.al.
found that local delivery and slow release of agonistic anti-
CD40 Ab to the tumor-draining area can effectively activate
local tumor-specific CD8T cells to become systemic effectors
without systemic toxicity or non-specific CTL activation (32).
And recent studies demonstrate that it’s possible to engineer a
tumor-targeted CD40 molecule by conjugating a CD40 agonist
mAb chemically with a tumor-homing peptide could potentially
maximize antitumor potency while limiting systemic toxicity in
clinical studies (33, 34). Therefore, it’s necessary to explore the
effect of these routes on HPV-specific Tscm cells and their safety
in clinical studies.
A more interesting thing was that the ratio of non-specific
Tscm cells in peripheral blood was much less than antigen-
specific Tscm cells whether the patients developed cancer or not.
These results indicated that Tscm cells possessed stronger antigen
specificity during pathogens infection. But Hong et al. showed
that the frequency of Tscm cells in NSCLC patients obviously
distinct from the healthy donors, including in the blood, lymph
nodes and TILs (35, 36). They analyzed the characteristics of T
cell subsets inNSCLC patients which didn’t take tumor specificity
into account. Perhaps most of immune cells surrounded by
tumor cells in TIL have been educated into antigen-specific cells.
Besides, it is uncertain whether the different sorts of cancers
may cause the different proportion of Tscm cells. Because Speiser
and his colleagues demonstrated that yellow-fever specific Tscm
could provide a long-term protection for humans (6). Antiviral
responses largely correlated to the change of human CD8+ T cell
subsets (6). And recent study has demonstrated that tumor cells
prevented stem-like CD8T cells from forming immune niches
within tumors in order to escape anti-tumor immune response,
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FIGURE 6 | High frequencies of Tscm might prevent the HPV infection to move on to the development of cancer. (A,B) Flow cytometry analysis of HPV16-specific
CD8+ T cells in PBMC from healthy donors (n = 6), HPV16 positive patients without tumor (n = 6) and HPV16 positive patients with cervical cancer (n = 6).
(C) HPV16-specific or non-specific CD8 Tscm cells defined as CD45RA+CD62L+CD95+CD122+ from CD8+ or CD8+Tet+T cells in PBMC from HPV16 positive
patients without or with cervical cancer were examined by flow cytometry. (D) The frequency of specific and non-specific CD8 Tscm cells in PBMC from HPV16
positive patients without tumor (n = 6) and HPV16 positive patients with cervical cancer (n = 6). (E) Relationship between CD40 and
CD62L+CD45RA+CD95+CD122+ were shown (npairs = 174). (F,G) K-M plots of HPV16 positive patients with cervical cancer for CD40 (F) and
CD62LCD45RACD95CD122 (G) respectively. Error bars represent the mean ± SD of three independent experiments. ***p < 0.001; n.s, p>0.05.
which explains why there was fewer CD8 Tscm cells in intra-
tumoral niche. This finding is consistent with our data acquired
from blood, spleen and lymph node (37).
Multiple studies have proved that CD40 plays a unique role
in motivating adaptive immunity. Activated CD40 signaling
facilitates long-lived memory CD8T cells differentiation while
CD8+ T cells can’t differentiate into memory cells without CD40
protein (38, 39). CD40 has been considered to promote the
generation of CD8+ central memory T cells (14). APCs infected
by CD40L-expressing recombinant vaccinia virus promote the
differentiation of naïve CD8+ T cell (CD8+CD45RO−CD62L+)
into central memory-like cells (CD8+CD45RO+CD62L+)(14).
However, little is known about the role of CD40 in Tscm. In
our study, we observed that the immunization of combined
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polyIC and CD40 were capable of inducing expansive HPV16
E7-specific CD8 Tscm cells more significantly than Tcm subset.
And obviously, the activation of CD40 signaling immensely
facilitates the generation of specific Tscm cells rather than non-
specific Tscm cells. There have been few reports on antigen-
specific Tscm cells because low frequency of these cells limits
detailed characterization (23). But it’s evident that only antigen-
specific Tscm can elicit long-lasting cellular immune response to
tumor antigen (23). Checkpoint inhibitors offer clinical benefit
to a limited number of patients, and response is heterogeneous,
mainly because there are different levels of immunogenicity
among cancer subtypes. And, treatment with these drugs is
also often associated with the induction of adverse autoimmune
reactions due to the lack of specificity of therapeutic effects (40).
That’s why engineering T-cells with chimeric antigen receptors
(CARs) and TCRs that target specific tumor antigens and re-
infusing them into patients have produced encouraging clinical
outcomes in clinical trials (41, 42). Our data is very meaningful
for solving off-target effect and short-time response in current
immunotherapy. Thus, understanding mechanisms how CD40
contributes to the generation of CD8 Tscm cells may develop
addition immune strategies for therapeutic vaccines.
Wnt/β-catenin signaling has emerged as a key regulator
in T cell development, including cell survival and stemness
maintenance (43, 44). Constitutive Wnt signaling activation
favors the formation of more antigen- specific memory CD8T
cells during initial immunization (17). Memory CD8T cells
with high Wnt signaling display increase recall proliferation
capacity compared with memory cells with low Wnt level, such
as short-lived effector cells and effector-like memory cells (45).
More recently, a number of evidences reveal that Wnt/β-catenin
signaling promotes the generation of CD8 memory stem cells
and maintains stemness in CD8 memory cells according to
arresting effector T cell differentiation (18). This is consistent
with our results that Wnt signaling inhibitor XAV-939 could
downregulate the level of CD8 Tscm cells. CD40L, which
sustains T cell activation by binding to CD40 (16, 46), has
been regarded as the upstream of Wnt10b primarily produced
by activated T cells (47). In WT mice, Wnt signaling can be
activated and Wnt10b increasingly produces by T cell but not
in CD40−/− mice (? ). The notion that Wnt10b is primarily
produced by activated T cells (47) and CD40L is a T cell surface
receptor required for sustaining T cell activation (48) accounts
for the finding. Collectively, these findings indicate the critical
role of CD40 in Wnt signaling activation. However, whether
CD40 potentiates antigen-specific CD8 Tscm generation through
activating Wnt/β-catenin signaling remains unclear. Our results
firstly demonstrated that CD40 promotes HPV16 E7-specific
Tscm upregulation in a Wnt-dependent manner. Recent studies
indicate that Tscm can accumulate by activating Wnt signaling
in vitro in PBMC from RCC patients (49), which explains why
CD40 can increase the proportion of antigen-specific Tscm and
may help to develop Tscm-based adoptive immunotherapy.
In summary, our data demonstrates CD40 potentiates
the antigen-specific CD8+ Tscm cells through Wnt/β-catenin
signaling to facilitate the effective long-term CD8T cell based
immunotherapy, and could develop an optimal immunization
strategy against cervical cancer, and these HPV16-specific Tscm
cells are associated with progression risks in CSCC patients.
Our study may provide a novel diagnosis and therapy strategy
for immunotherapy.
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